Press releaseGlobe Newswire
Spyre Therapeutics
SYRE · NASDAQ
$91.40+$6.68 (+7.88%)TodayMarket closed ·
Prev close $84.72
Latest news
- NewsAvi Kapoor
Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings
- Press releaseGlobe Newswire
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
- Press releaseGlobe Newswire
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
- NewsAvi Kapoor
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
- Press releaseGlobe Newswire
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
- NewsVandana Singh
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles
- NewsAvi Kapoor
Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
- Press releaseGlobe Newswire
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
- Press releaseGlobe Newswire
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- NewsAvi Kapoor
Goldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On Tuesday
- NewsVandana Singh
What's Going On With Spyre Therapeutics Stock On Wednesday?
- NewsAvi Kapoor
FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
- Press releaseGlobe Newswire
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
- Press releaseGlobe Newswire
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
- Press releaseGlobe Newswire
Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- NewsAvi Kapoor
Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- Press releaseGlobe Newswire
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
- NewsAvi Kapoor
Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- NewsGianni di Poce
The Insider Report: The Flush Accelerates Under the Surface as Internals Tell the Story
- News
Earnings Summary: Spyre Therapeutics Q4
- NewsAvi Kapoor
This Chevron Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
- NewsAvi Kapoor
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday
- Press releaseGlobe Newswire
Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum
- Press releasePRNewswire
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
- Press releasePRNewswire
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025
- Press releasePRNewswire
Spyre Therapeutics Announces Grants of Inducement Awards
- Press releasePRNewswire
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
- Press releasePRNewswire
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Press releasePRNewswire
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
- Press releasePRNewswire
Spyre Therapeutics Announces Grants of Inducement Awards
- NewsAvi Kapoor
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
- Press releasePRNewswire
Spyre Therapeutics Announces Grants of Inducement Awards
- Press releasePRNewswire
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
- Press releasePRNewswire
Spyre Therapeutics Announces Grants of Inducement Awards
- Press releasePRNewswire
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Press releasePRNewswire
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
- Press releasePRNewswire
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
- Press releasePRNewswire
Spyre Therapeutics Announces Grants of Inducement Awards
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
- Press releasePRNewswire
Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
- Press releasePRNewswire
Spyre Therapeutics Announces Grants of Inducement Awards
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.